Doximity Q1 Earnings Call Highlights
Doximity (NYSE:DOCS) reported Q1 results, citing its expert-verified drug reference and physician-reviewed AI tools. It said it has 165 live health-system AI clients, including Northwestern, Penn Medicine and Michigan. AI Search launched in late April; no Q1 revenue recognized, with most expected in fiscal Q3. Q1 revenue retention: 112% top 20, 107% overall. Q2 revenue forecast $170M-$171M; FY2027 outlook raised to $671M-$681M.
How this was made
The 30-second read
Why it matters
Traders can update expectations for revenue recognition timing (AI Search largely recognized in fiscal Q3) and for profitability (adjusted EBITDA margin guidance) based on the provided Q2 and FY27 ranges.
Market read
Guidance update with explicit revenue and adjusted EBITDA ranges, plus a clear explanation of AI Search revenue recognition timing and expectations for FY27 growth.
What to watch
Gross margin is expected to stay in the mid-to-high-80% range despite AI investment, but the article does not quantify how much incremental AI Search contract wins translate into recognized revenue timing beyond Q3.
Background
Doximity’s Q1 call focused on its clinical AI suite and a newer AI Search product launched in late April, plus customer engagement and retention metrics.
Ticker impact
Doximity guided fiscal Q2 revenue to $170M-$171M and raised fiscal 2027 revenue to $671M-$681M, citing AI Search pipeline and stability in pharma budgets.
Likely supportive for near-term sentiment given raised FY outlook, but tempered by modest Q2 growth and delayed AI Search revenue recognition.
The article discloses explicit guidance ranges (Q2 revenue, Q2 adjusted EBITDA, FY27 revenue, FY27 adjusted EBITDA) plus the key driver that most AI Search revenue is expected to be recognized in fiscal Q3.
Market effects
Highlights demand for clinical AI and physician workflow tools, with monetization tied to hospital and pharma budgets.
No specific regional market impact beyond US healthcare IT spending.
Limited direct global relevance; story is primarily US healthcare provider and pharma commercial budgets.
Counterpoint
The raised FY27 outlook may rely on AI Search commercial pipeline, but Q2 growth is only 1% and AI Search revenue is largely deferred to fiscal Q3.
Key entities
- public_companyDoximity
NYSE-listed digital professional network and clinical AI platform provider; reported Q1 highlights and issued Q2 and FY27 guidance.
- productAI Search
Late-April-launched AI Search offering for pharmaceutical customers; revenue recognition expected to be weighted toward fiscal Q3.
